Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by ...

Ocugen Shares Phase II OCU410 Data Showing 31% Slower GA Lesion Growth at 12 Months

Ocugen (NASDAQ:OCGN) presented top-line 12-month results from its Phase II ArMaDa clinical trial evaluating OCU410, a ...
Ophthalmology Times

Ocugen completes dosing early in phase 2/3 GARDian3 trial for Stargardt disease

The ongoing GARDian3 study is designed to assess whether a single subretinal administration of OCU410ST can slow structural ...
Ophthalmology Times

First patient dosed in phase I/II trial of complement-targeting gene therapy for geographic atrophy

A first-in-human clinical trial evaluating an investigational gene therapy targeting complement-mediated pathways in ...

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular ...

Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< ...
Precision Medicine Online

Ocugen to Launch Phase III Trial of Geographic Atrophy Gene Therapy This Year

The firm selected the dose of OCU410 to be studied in the pivotal trial based on positive results from the company's Phase II ArMaDa trial.
FierceBiotech

Atsena eye disease gene therapy hits safety goals, closes retinal splits in phase 1/2

Hot on the heels of a $150 million fundraise, Atsena Therapeutics is back with early-stage data for the company’s eye disease gene therapy. The candidate improved the structure and function of the ...

OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development

OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad platform.